Skip to content
Health
Link copied to clipboard
Link copied to clipboard

Jim Wilson has 2 new promising gene therapy studies, but says investment in the cutting-edge field has ‘gotten worse’

Wilson speaks about the Penn studies and the recent mixed results for Sarepta's muscular dystrophy drug.

Jim Wilson, director of the University of Pennsylvania's gene therapy program, led two new studies on the long-term effects of the cutting-edge treatments.
Jim Wilson, director of the University of Pennsylvania's gene therapy program, led two new studies on the long-term effects of the cutting-edge treatments.Read moreDaniel Burke Photography
    by Tom Avril
    Published